With 4.28 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.31 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.9478 whereas the lowest price it dropped to was $0.8295. The 52-week range on LXRX shows that it touched its highest point at $3.73 and its lowest point at $0.62 during that stretch. It currently has a 1-year price target of $3.60. Beta for the stock currently stands at 1.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LXRX was up-trending over the past week, with a rise of 29.22%, but this was up by 43.06% over a month. Three-month performance dropped to -44.98% while six-month performance fell -41.88%. The stock lost -41.88% in the past year, while it has gained 25.92% so far this year. A look at the trailing 12-month EPS for LXRX yields -0.75 with Next year EPS estimates of -0.46. For the next quarter, that number is -0.13. This implies an EPS growth rate of 14.05% for this year and 31.83% for next year.
Float and Shares Shorts:
At present, 361.49 million LXRX shares are outstanding with a float of 168.72 million shares on hand for trading. On 2024-12-13, short shares totaled 31.28 million, which was 864.9999999999999 higher than short shares on 1731628800. In addition to Mr. Brian T. Crum as the firm’s Senior VP, General Counsel & Secretary, Dr. Alan J. Main Ph.D. serves as its Executive Vice President of Innovation & Chemical Sciences.
Institutional Ownership:
Through their ownership of 0.81911004 of LXRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, LXRX reported revenue of $1750000.0 and operating income of -$63693000.0. The EBITDA in the recently reported quarter was -$60123000.0 and diluted EPS was -$0.18.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LXRX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LXRX analysts setting a high price target of 10.0 and a low target of 0.8, the average target price over the next 12 months is 3.6. Based on these targets, LXRX could surge 975.27% to reach the target high and fall by -13.98% to reach the target low. Reaching the average price target will result in a growth of 287.1% from current levels.
Analysts have provided yearly estimates in a range of -$0.58643 being high and -$0.76133 being low. For LXRX, this leads to a yearly average estimate of -$0.67902.
